

## Summary of Product Characteristics

### 1 NAME OF THE VETERINARY MEDICINAL PRODUCT

Cyclo Spray, 2.45 % w/w for cattle, sheep and pigs.

### 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Per container of 270 mL:

**Active Substance:**

Chlortetracycline HCl.

The active ingredient content is 2.45 % w/w (equivalent to 3.210 g)

**Excipients:**

Patent Blue V (E 131) 0.15 % w/w (equivalent to 0.196 g)

Butane 100 68.77% w/w(equivalent to 89.920g)

Per container of 520 mL:

**Active Substance:**

Chlortetracycline HCl.

The active ingredient content is 2.45 % w/w (equivalent to 6.420 g)

**Excipients:**

Patent Blue V (E 131) 0.15 % w/w (equivalent to 0.392 g)

Butane 100 68.77% w/w(equivalent to 179.840g)

For a full list of excipients, see section 6.1.

### 3 PHARMACEUTICAL FORM

Cutaneous Spray, Suspension.

### 4 CLINICAL PARTICULARS

#### 4.1 Target Species

Cattle, sheep and pigs.

#### 4.2 Indications for use, specifying the target species

- Treatment of superficial traumatic or surgical wounds contaminated with chlortetracycline-sensitive agents.
- The product can be used as part of a treatment for superficial skin and claw/hoof infections, in particular interdigital dermatitis (foot rot and foul in the foot) and digital dermatitis caused by micro-organisms sensitive to chlortetracycline.

### 4.3 Contraindications

Do not use in case of hypersensitivity to tetracyclines or to other ingredients of the product. Do not use on the udder of lactating animals if milk is intended for human consumption.

### 4.4 Special warnings for each target species

None

### 4.5 Special precautions for use

#### Special precautions for use in animals

Protect the eyes when spraying in the vicinity of the head. Clean the affected area thoroughly before spraying. After administration on the claw/hoof the animal should be kept on a dry ground at least for an hours time. Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to chlortetracycline and may decrease the effectiveness of treatment with other tetracyclines, due to the potential for cross resistance.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals

- Because of the risk of sensitisation and contact dermatitis, skin contact should be avoided.
- Wear appropriate impermeable gloves whilst handling the product.
- Because of risk of eye irritation, contact with the eyes should be avoided. Protect the eyes and face.
- Do not spray on an open flame or other ignition source.
- Do not pierce or burn, even after use.
- Avoid inhaling vapours. Apply the product in open air or in sufficiently ventilated area.
- Wash hands after use.
- Do not eat or smoke whilst administering the product.

### 4.6 Adverse reactions (frequency and seriousness)

Hypersensitivity reactions may occur rarely.

### 4.7 Use during pregnancy, lactation or lay

Following cutaneous administration of the product, chlortetracycline is not absorbed, nor excreted with the milk. Therefore, the product is safe for use during pregnancy and lactation.

### 4.8 Interaction with other medicinal products and other forms of interaction

After cutaneous administration of chlortetracycline spray, chlortetracycline is not absorbed. Parenteral or oral administered antibiotics will not penetrate the dermis. Therefore no interactions are to be expected. No data on interactions with other local treatments are available.

## 4.9 Amounts to be administered and administration route

The product is indicated for cutaneous administration. Shake the container thoroughly before spraying. The container should be held at a distance of approximately 15-20 cm from the area to be sprayed; spray for 3 seconds until the treatment-area is evenly coloured.

In case of claw/hoof infections this treatment should be repeated after 30 seconds.

- For treatment of superficial traumatic or surgical wounds contaminated with chlortetracycline-sensitive agents a single administration is recommended.
- For treatment of Dermatitis Digitalis administration twice with a 30 second interval during three consecutive days once or twice daily is recommended.

For treatment of other claw/hoof infections (foot rot and foul in the foot), administration twice with a 30 second interval once or twice daily is recommended. Dependent on the seriousness of the injury and the rate of improvement treatment should be repeated within 1 to 3 days.

## 4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

Not applicable

## 4.11 Withdrawal Period(s)

Meat : zero days

Milk : zero days

See also 4.3 contraindications

## 5 PHARMACOLOGICAL or IMMUNOLOGICAL PROPERTIES

Pharmacotherapeutic group: tetracycline antibiotics.

ATCvet code: QD06A

### 5.1 Pharmacodynamic properties

In vitro, chlortetracycline is primarily bacteriostatic. Chlortetracycline exerts its action by inhibiting the protein synthesis of the bacterial cell. Especially cell-division and the formation of the cell wall are impaired. Chlortetracycline binds to receptors on the 30S-subunit of the bacterial ribosome where they interfere with the binding of the aminoacyl-transfer RNA to the acceptor site on the messenger RNA ribosome complex.

### 5.2 Pharmacokinetic properties

Following cutaneous administration of chlortetracycline spray, chlortetracycline absorption is negligible. Therefore the product will only have a local effect, no systemic effects are to be anticipated.

## 6 PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

Colloidal anhydrous silica

Isopropyl alcohol

Patent blue V (*E-131*)

Sorbitan trioleate

Butane 100

## **6.2 Incompatibilities**

Not applicable.

## **6.3 Shelf-life**

Shelf-life of the veterinary medicinal product as packaged for sale: 3 years.

## **6.4 Special precautions for storage**

Extremely flammable aerosol. Pressurised container: May burst if heated.

Protect from sunlight. Do not expose to temperatures exceeding 50°C.

Keep away from heat/hot surfaces/sparks/open flames and other ignition sources. No smoking.

## **6.5 Nature and composition of immediate packaging**

270 ml pressurised container of coated tin plate with a plastic valve mechanism and spraying nozzle.

520 ml pressurised container of coated tin plate with a plastic valve mechanism and spraying nozzle.

## **6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

## **7 MARKETING AUTHORISATION HOLDER**

Eurovet Animal Health B.V.  
Handelsweg 25, PO Box 179,  
5530 AD Bladel  
The Netherlands

## **8 MARKETING AUTHORISATION NUMBER(S)**

VPA: 10989/049/001

## **9 DATE OF THE FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

26<sup>th</sup> August 2009

## **10 DATE OF REVISION OF THE TEXT**

January 2017